Related Experiment Video
Updated: Sep 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Beyond pooled analysis: sex-specific cardiovascular adverse event reporting signals with antiarrhythmic drugs in
Mostafa A Khalifa1, Mohammad Najm Dadam2, Layan S Aldib3
1Faculty of Medicine, Cairo University, Cairo, Egypt.
Abstract:
Sex differences in drug metabolism and cardiac electrophysiology may influence the cardiovascular safety profiles of antiarrhythmic drugs (AADs). However, pharmacovigilance studies often pool data, potentially obscuring sex-specific cardiovascular adverse event (CV-AE) reporting patterns. We aim to investigate sex-specific CV-AE reporting profiles associated with commonly used antiarrhythmic drugs using pharmacovigilance data. We analyzed 122,853 medication-role records representing 38,430 unique FAERS reports involving eight AADs. Disproportionality analyses defined index-drug exposure by the primary-suspect role, whereas the report-level XGBoost pipeline separately encoded primary-suspect drugs and secondary-suspect or concomitant medications. Analyses included pooled and sex-stratified disproportionality, drug-adjusted common odds ratios, and a gradient-boosting machine learning model to assess ventricular arrhythmia (VA) reporting patterns. Sex-stratified analysis uncovered "hidden" associations undetected in pooled data, including propafenone-QT prolongation in men and amiodarone-QT prolongation in women. Adverse event profiles were often drug-specific and opposing: cardiogenic shock showed higher reporting odds among males for sotalol, whereas flecainide showed higher reporting odds in females. After adjustment, women had higher odds of torsade de pointes and men of ventricular arrhythmia. However, a machine learning model for VA demonstrated that sex contributed modestly (1.4% SHAP contribution) compared with co-medications and the primary drug, though drug-specific associations differed. Sex-specific CV-AE profiles reporting patterns are often masked in pooled analyses, underscoring the need for sex-stratified pharmacovigilance to guide personalized antiarrhythmic therapy. The identified associations should be considered hypothesis-generating and require validation in datasets with richer clinical information.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
10:41Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
Published on: September 13, 2022
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Drug Toxicity: Risk factors